Patent intelligence · US
US 9833421
Method for synthesizing (E)-anethol and related compounds by cross coupling reaction of potassium allyltrifluroborate and 4-bromoanisole and aryl halides
Method for synthesizing (E)-anethol and related compounds by cross coupling reaction of potassium allyltrifluroborate and 4-bromoanisole and…
Patent details — US 9833421
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2017
- Expiration
- Nov 30, 2037
- Applicant
- Tennessee Board of Regents
- Claims
- 11
- CPC classes
- A61K, A61K31/085, A61P, A61P31/14
Quick answer
US 9833421 (Method for synthesizing (E)-anethol and related compounds by cross coupling reaction of potassium allyltrifluroborate and 4-bromoanisole and aryl halides) is held by Tennessee Board of Regents. Status: granted. Granted Dec 5, 2017. Expires Nov 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tennessee Board of Regents
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/085, A61P, A61P31/14, A61P31/18, A61P31/22
More from Tennessee Board of Regents
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9833421?
US 9833421 (Method for synthesizing (E)-anethol and related compounds by cross coupling reaction of potassium allyltrifluroborate and 4-bromoanisole and aryl halides) is held by Tennessee Board of Regents. Status: granted. Granted Dec 5, 2017. Expires Nov 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9833421?
Tennessee Board of Regents is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9833421 expire?
Our index shows an expiration date of Nov 30, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.